I think Leo will also apply for the Breakthrough T
Post# of 72440
"Given the limited treatment options, devastating effects, and small patient population, Cellceutix believes that retinoblastoma would make an excellent candidate for a phase 2/3 trial once our present phase 1 trial is completed. It would qualify for a number of FDA programs (Orphan, Fast Track and Breakthrough) that can exponentially shrink development time, should clinical data support the current research."
http://cellceutix.com/cellceutix-plans-for-fu...akzQf.dpbs